

**ATTENTION PHARMACISTS:**  
**PLEASE POST THIS IN YOUR PHARMACY**

**KwikPen Prefilled with the Humalog® Brand of Insulins**



*Contact your wholesaler for normal ordering procedures*

**For use with all formulations of Humalog:**

**Humalog® KwikPen®**

insulin lispro injection (rDNA origin)

**Humalog<sup>mix</sup> 50/50™ KwikPen®**

50% insulin lispro protamine suspension  
50% insulin lispro injection (rDNA origin)

**Humalog<sup>mix</sup> 75/25™ KwikPen®**

75% insulin lispro protamine suspension  
25% insulin lispro injection (rDNA origin)

**How does KwikPen fit in?**

- Small size
- Lightweight and portable
- Short thumb-reach at high doses
- Easy to set the dose\*<sup>1</sup>
- Easy to dial up and back down for dose correction
- Easy to dispense the maximum dose of 60 units\*<sup>1</sup>
- Does not need refrigeration after first use

\*KwikPen Design Validation User Study included adult male and female participants with type 1 and type 2 diabetes. Of the total 150 study participants, 56 were insulin naïve, 42 were currently administering insulin with a vial and syringe and 52 were experienced insulin pen users.

<sup>1</sup> Data on file (HUM20071024A)

**Please visit [www.Humalog.com](http://www.Humalog.com) today to view:**

- A demonstration on the use of KwikPen and full user manual
- Prescribing information on the Humalog Brand of Insulins
- Downloadable patient educational materials in multiple languages

Or contact The Lilly Answers Center at 800-Lilly-Rx (800-545-5979)

KwikPen prefilled with the Humalog Brand of Insulins has color-differentiated labeling.

Humalog®, Humalog® Mix75/25™ and Humalog® Mix50/50™ are also available by prescription in the original Humalog & Humalog Mixtures Prefilled Pen.



**Lilly**

**Please see Important Safety Information on back and  
accompanying full Prescribing Information**

	<b>NDC, UPC, &amp; Lilly Product Codes</b>	<b>Box of 5 Pens: Dimensions</b>	<b>Box of 5 Pens: Weight</b>
<b>Humalog KwikPen</b> Prefilled insulin delivery device, 3.0 ml (Box of 5 pens)	NDC: 0002-8799-59 UPC: 3-0002-8799-59-8 LILLY: HP8799	5.8 in x 3.6 in x 1.2 in	6.6 oz
<b>Humalog MIX75/25 KwikPen</b> Prefilled insulin delivery device, 3.0 ml (Box of 5 pens)	NDC: 0002-8797-59 UPC: 3-0002-8797-59-4 LILLY: HP8797	5.8 in x 3.6 in x 1.2 in	6.6 oz
<b>Humalog MIX50/50 KwikPen</b> Prefilled insulin delivery device, 3.0 ml (Box of 5 pens)	NDC: 0002-8798-59 UPC: 3-0002-8798-59-1 LILLY: HP8798	5.8 in x 3.6 in x 1.2 in	6.6 oz

Humalog (insulin lispro injection [rDNA origin]), Humalog Mix75/25 (75% insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin]), and Humalog Mix50/50 (50% insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin]) are for use in patients with diabetes mellitus for the control of hyperglycemia. Humalog should be used with longer-acting insulin, except when used in combination with sulfonylureas in patients with type 2 diabetes.

#### **Important Safety Information**

Humalog differs from regular human insulin by its rapid onset of action as well as a shorter duration of action. Therefore, when used as a mealtime insulin, Humalog insulins (Humalog, Humalog Mix75/25, and Humalog Mix50/50) should be given within 15 minutes before a meal. Humalog can also be given immediately after a meal. Due to the short duration of action of Humalog, patients with type 1 diabetes also require a longer-acting insulin to maintain glucose control (except when using an insulin pump). Glucose monitoring is recommended for all patients with diabetes.

The safety and effectiveness of Humalog in patients less than 3 years of age have not been established. Safety and effectiveness of Humalog Mix75/25 and Humalog Mix50/50 in patients less than 18 years of age have not been established. There are no adequate and well-controlled clinical studies of the use of Humalog insulins in pregnant or nursing women.

**Starting or changing insulin therapy should be done cautiously and only under medical supervision.**

Patients should be advised not to mix Humalog Mix75/25 or Humalog Mix50/50 with another insulin. Humalog insulins are contraindicated during episodes of hypoglycemia and in patients sensitive to Humalog or one of its excipients.

#### **Hypoglycemia**

Hypoglycemia is the most common adverse effect associated with insulins, including Humalog insulins. Hypoglycemia can happen suddenly, and symptoms may be different for each person and may change from time to time. Severe hypoglycemia can cause seizures and may be life-threatening.

#### **Other Side Effects**

Other potential side effects associated with the use of insulins include: hypokalemia, weight gain, lipodystrophy, and hypersensitivity. Systemic allergy is less common, but may be life-threatening. Because of the difference in action of Humalog insulins, care should be taken in patients in whom hypoglycemia or hypokalemia may be clinically relevant (eg, those who are fasting, have autonomic neuropathy or renal impairment, are using potassium-lowering drugs, or taking drugs sensitive to serum potassium level).

**For additional safety profile and other important prescribing considerations, see the accompanying full Prescribing Information.**

**Please see full user manual that accompanies the Pen.**

Humalog<sup>®</sup>, Humalog<sup>®</sup> Mix75/25<sup>™</sup> and Humalog<sup>®</sup> Mix50/50<sup>™</sup> are registered trademarks of Eli Lilly and Company. Humalog<sup>®</sup> KwikPen<sup>™</sup>, Humalog<sup>®</sup> Mix75/25 KwikPen<sup>™</sup> and Humalog<sup>®</sup> Mix50/50 KwikPen<sup>™</sup> are trademarks of Eli Lilly and Company. Humalog<sup>®</sup> KwikPen<sup>™</sup>, Humalog<sup>®</sup> Mix75/25 KwikPen<sup>™</sup> and Humalog<sup>®</sup> Mix50/50 KwikPen<sup>™</sup> are available by prescription only.